Import from "@/components/mdx"

Praluent (Alirocumab) Manufacturing, Supply and Shortage History

What Praluent Is and How It Works

Praluent is a fully human monoclonal antibody that blocks proprotein convertase subtilisin/kexin type 9, the protein that degrades LDL receptors on liver cells. When PCSK9 is inhibited, more LDL receptors recycle back to the hepatocyte surface, pulling more LDL-cholesterol out of circulation. The result is an LDL reduction of 50-60% on top of background statin therapy.

This mechanism is entirely different from statins, which block cholesterol synthesis. That distinction matters for women whose LDL remains dangerously elevated despite maximum tolerated statin doses, a group that includes those with heterozygous familial hypercholesterolemia (HeFH), homozygous FH, or established atherosclerotic cardiovascular disease (ASCVD).

The PCSK9 Gene and Women

The PCSK9 gene was discovered in a French family with autosomal dominant hypercholesterolemia in 2003, and women carry gain-of-function mutations at the same population frequency as men. What differs is the clinical expression. Pre-menopausal women benefit from estrogen-mediated upregulation of hepatic LDL receptors, which can partially offset high circulating PCSK9. Estrogen suppresses PCSK9 expression in the liver, meaning your LDL may appear deceptively controlled during your reproductive years even if you carry an FH mutation, then climb sharply at perimenopause when estrogen falls. If you have been told your cholesterol "isn't that bad yet," and you are approaching or in perimenopause, that reassurance may need revisiting.

Approved Indications for Women

Praluent carries FDA approval for:

• Adults with HeFH
• Adults with established ASCVD who need additional LDL lowering on maximally tolerated statin therapy

The FDA label does not yet separately specify dosing by sex, though pharmacokinetic data are available (see the Sex-Specific Pharmacokinetics section below).

The ODYSSEY OUTCOMES Trial: What the Data Actually Show

ODYSSEY OUTCOMES enrolled 18,924 patients who had experienced an acute coronary syndrome (ACS) within the preceding year and were already on high-intensity statin therapy. Published in the New England Journal of Medicine in 2018, the trial randomized participants to alirocumab 75 mg every 2 weeks (titrated up to 150 mg if needed) versus placebo.

The primary outcome, a composite of coronary heart death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization, was reduced by 15% in the alirocumab arm (HR 0.85, 95% CI 0.78-0.93). All-cause mortality showed a nominal 15% reduction that reached statistical significance in a pre-specified sensitivity analysis.

Women in ODYSSEY OUTCOMES

Approximately 25% of ODYSSEY OUTCOMES participants were women, a representation gap that the trial authors acknowledged. Subgroup analyses suggested consistent directional benefit across sexes, but the confidence intervals for the female subgroup alone were wide enough to preclude definitive sex-specific conclusions. This is a real evidence gap. The cardiovascular outcome data in women with FH or post-ACS ASCVD are extrapolated from trials where women were enrolled at lower rates than their disease burden warrants. WomanRx will update this section if sex-stratified data from ongoing registries change the picture.

LDL Targets After ACS: The Numbers That Guide Your Prescription

The 2018 ACC/AHA Cholesterol Guideline recommends an LDL goal of <70 mg/dL for very high-risk ASCVD, with consideration of adding a non-statin agent when LDL remains at 70 mg/dL or above despite maximum tolerated statin plus ezetimibe. PCSK9 inhibitors are the recommended next step. For women post-ACS who are also perimenopausal or postmenopausal, hitting that target often requires Praluent or evolocumab because statins alone frequently fall short.

How Praluent Is Manufactured

Praluent is a biologic, not a small molecule. It cannot be synthesized in a reactor like atorvastatin. Instead, it is grown inside living Chinese hamster ovary (CHO) cell lines, a standard platform for recombinant monoclonal antibody production.

The Biologic Production Chain

The manufacturing process follows this general sequence:

1. Cell bank maintenance. A master cell bank of CHO cells expressing the alirocumab gene is maintained under strict cryogenic conditions. Any contamination at this stage stops production.
2. Upstream bioreactor culture. Cells are expanded in progressively larger bioreactors, reaching production scale over several weeks. Environmental controls, pH, dissolved oxygen, and nutrient feeds must remain tightly specified.
3. Harvest and clarification. The cell culture fluid is harvested and clarified by centrifugation and depth filtration to remove cells and debris.
4. Downstream purification. Protein A affinity chromatography captures the antibody, followed by additional chromatography steps and viral inactivation. This is where product-specific contaminants are removed.
5. Formulation and fill-finish. The purified antibody is formulated into the final buffer system, filled into single-dose pre-filled pens or syringes, and inspected.
6. Quality release testing. Each batch undergoes potency, purity, identity, and safety testing before release. This process takes weeks to months.

Regeneron's primary manufacturing for Praluent takes place at its Rensselaer, New York facility, with Sanofi managing portions of commercial fill-finish and distribution through its European network. Regeneron's manufacturing platform is FDA-inspected under 21 CFR 600 and subject to European Medicines Agency oversight for EU distribution.

Why Biologic Manufacturing Creates Longer Lead Times

A statin shortage resolves relatively quickly because chemical synthesis can be scaled in weeks. A biologic shortage takes months to resolve at minimum, because every new production run requires cell expansion, a multi-week bioreactor culture cycle, and full quality release testing before any vials ship. Downstream purification equipment is often shared across multiple biologic programs at large manufacturers, creating internal scheduling competition. This structural feature of biologic production is why supply interruptions in monoclonal antibodies carry more clinical weight than shortages of generic pills.

Praluent Supply and Shortage History

2015 to 2018: Launch and Payer Friction

The FDA approved alirocumab in July 2015, alongside evolocumab, which was approved one month later. Initial list prices were approximately $14,000 per year, triggering an immediate pushback from pharmacy benefit managers (PBMs) and payers. Prior authorization denial rates for PCSK9 inhibitors exceeded 50% in 2016-2017, meaning many women with documented FH or post-ACS ASCVD were denied coverage despite meeting guideline criteria. This was not a manufacturing shortage, but it created the same clinical problem: patients could not access the drug.

For women specifically, the access problem was compounded by the fact that FH is underdiagnosed in women. Women with FH are less likely than men to receive a clinical FH diagnosis, less likely to be on high-intensity statin therapy, and therefore less likely to have documented prior statin failure that triggers PCSK9 inhibitor authorization.

2019: Sanofi's Threatened US Market Withdrawal

In March 2019, Sanofi announced it was considering withdrawing Praluent from the US market, citing a loss in a patent dispute with Amgen (which makes evolocumab, sold as Repatha). The Federal Circuit Court of Appeals had invalidated several Regeneron/Sanofi patents covering PCSK9 antibody technology. Sanofi indicated that without patent protection, the commercial case for maintaining US supply at the existing price was uncertain.

This announcement created genuine clinical concern. Patients already stabilized on alirocumab faced the prospect of switching to evolocumab or losing access entirely. Specialty pharmacies and healthcare systems began counseling at-risk patients. The Supreme Court ultimately declined to hear the patent dispute in January 2020, and Sanofi reached a confidential settlement with Amgen, removing the market-exit threat.

The episode highlighted a risk unique to biologic drugs with limited competition: a commercial or legal dispute between two companies can threaten supply for thousands of patients, with no generic alternative available.

2020 to 2021: COVID-19 Manufacturing Pressures

The pandemic disrupted biologic manufacturing broadly. CHO-based production facilities faced challenges including staff shortages, supply-chain constraints on single-use bioreactor components, and regulatory inspection delays. Praluent was not the subject of an official FDA drug shortage designation during this period, but anecdotal reports from specialty pharmacies described intermittent delays in filling orders, particularly for the 150 mg pen.

Regeneron's Rensselaer facility was simultaneously under pressure to support antibody programs beyond Praluent, including the company's COVID-19 antibody cocktail (casirivimab and imdevimab). Shared manufacturing infrastructure means that prioritization decisions at the company level can affect PCSK9 inhibitor supply without any formal shortage declaration.

2022 to 2025: Relative Stability, Ongoing Access Problems

No formal FDA-designated shortage of alirocumab appears in the FDA Drug Shortage Database as of early 2025. Supply has been relatively stable, but access remains the dominant bottleneck. Prior authorization burdens have eased somewhat after the 2023 ACC consensus pathway for PCSK9 inhibitor access, which explicitly advocates for streamlined authorization for patients with FH or very high-risk ASCVD.

No FDA-approved biosimilar to alirocumab exists as of early 2025, in contrast to the biosimilar market for other biologic drug classes. The absence of a biosimilar means there is no lower-cost fallback if Regeneron or Sanofi faces manufacturing disruption.

What to Do If Your Praluent Is Delayed or Unavailable

If you cannot access alirocumab:

• Switch to evolocumab (Repatha). Both are PCSK9 inhibitors with comparable LDL reduction; evolocumab 140 mg every 2 weeks or 420 mg monthly are the standard alternatives. Clinical equivalence is supported by network meta-analyses.
• Confirm your prior authorization is current. Many delays are administrative rather than physical supply failures. Your specialty pharmacy or cardiologist's office can expedite.
• Ask about patient assistance programs. The Praluent patient assistance program (MyPraluent) can reduce out-of-pocket cost to as little as $0 per month for eligible commercially insured patients.
• Do not abruptly stop without a plan. Missing doses of a PCSK9 inhibitor does not cause rebound as seen with some other agents, but any gap in LDL lowering in a post-ACS patient carries real cardiovascular risk. Contact your prescriber within 48 hours of a supply problem.

Sex-Specific Pharmacokinetics and Dosing in Women

The alirocumab label notes that body weight and sex affect pharmacokinetics, though the current dosing regimen is not adjusted by sex in practice. Women, who on average weigh less than men enrolled in ODYSSEY OUTCOMES, tend to achieve higher peak drug concentrations per dose than heavier male participants. This has not translated into a separate dosing recommendation, but it is a relevant consideration when tolerability is discussed.

Post-hoc pharmacokinetic modeling from the ODYSSEY program confirmed that the 75 mg starting dose achieves adequate LDL suppression in most patients regardless of sex, with dose escalation to 150 mg reserved for non-responders at 4 weeks. Women who are at the lower end of the body-weight spectrum may achieve their LDL target at 75 mg without escalation.

Hormonal Status and LDL: The Perimenopausal Window

LDL rises an average of 10-14 mg/dL in the menopausal transition, and the rise can be steeper in women with pre-existing FH. This is not simply aging. The drop in estrogen removes a natural suppressor of hepatic PCSK9 expression, increasing PCSK9 levels and reducing LDL receptor recycling. The clinical result: a woman who was tolerating high-intensity statin therapy with an LDL of 80 mg/dL at age 45 may present at age 52 with an LDL of 110 mg/dL on the same statin dose, and that is biologically predictable rather than surprising.

For perimenopausal and postmenopausal women with FH or ASCVD, this makes PCSK9 inhibitor therapy a particularly high-value intervention. Menopausal hormone therapy (MHT) does have LDL-lowering effects through estrogen's action on LDL receptors, but MHT is not prescribed as a cholesterol treatment and is not appropriate for all women. It does not replace dedicated lipid-lowering therapy in high-risk patients.

PCOS and Elevated PCSK9

Women with polycystic ovary syndrome have measurably higher circulating PCSK9 levels compared to age- and weight-matched controls, which may partially explain the excess cardiovascular risk in PCOS beyond what insulin resistance alone accounts for. If you have PCOS with dyslipidemia that is not responding adequately to lifestyle changes and metformin, PCSK9 inhibitor therapy may be a future option, though most women with PCOS are in their reproductive years when pregnancy contraindication is directly relevant.

Pregnancy, Lactation, and Contraception

Praluent is contraindicated in pregnancy. This is non-negotiable.

IgG1 monoclonal antibodies cross the placental barrier through neonatal Fc receptor-mediated active transport, predominantly in the second and third trimesters. Because PCSK9 plays a role in fetal lipid metabolism and organ development, exposing a fetus to PCSK9 blockade during development raises theoretical harm that has not been studied in controlled human trials. Animal studies using doses producing exposures higher than therapeutic human levels showed no malformations, but animal reproductive toxicology does not rule out human risk, and the drug's mechanism is biologically active in developing fetal tissue.

What This Means for You by Life Stage

Reproductive years (18-40). If you have FH or very high-risk lipids and are sexually active, reliable contraception is required while on alirocumab. Long-acting reversible contraception (an IUD or implant) offers the strongest protection. If you are planning a pregnancy, work with your cardiologist and OB-GYN to establish a statin washout plan and a PCSK9 inhibitor discontinuation timeline before conception. The half-life of alirocumab is approximately 17-20 days, meaning it takes roughly 85-100 days to fall below detectable levels after your last injection.

Trying to conceive. Stop alirocumab before you begin attempting pregnancy. There is no established safe window for continued use. The FDA prescribing information states that the drug should be discontinued as soon as pregnancy is recognized if it was not stopped beforehand.

Pregnancy itself. Do not use alirocumab during pregnancy. If you discover you are pregnant while on therapy, contact your cardiologist and OB immediately. Cardiovascular risk management during pregnancy in women with FH may involve bile acid sequestrants (the only lipid-lowering agents with a reasonable pregnancy safety profile) or LDL apheresis in severe cases.

Postpartum and lactation. Human data on alirocumab in breast milk are absent. IgG antibodies are present in human colostrum and breast milk in small quantities, and the extent of neonatal systemic absorption from breast milk IgG is considered low due to intestinal degradation. The risk is theoretical rather than established. Most clinicians and the FDA label recommend avoiding alirocumab while breastfeeding until adequate human data exist.

Perimenopause and postmenopause. This is where the benefit-risk calculus most clearly favors alirocumab in women with FH or established ASCVD. Contraception requirements no longer apply. The cardiovascular risk window is open. If you are postmenopausal and your LDL remains above 70 mg/dL on maximum tolerated statin plus ezetimibe, you have a strong evidence-based case for PCSK9 inhibitor therapy.

Who Praluent Is Right For, and Who Should Wait

Women Who Are Strong Candidates

• Postmenopausal women with HeFH and LDL above 100 mg/dL on maximum statin therapy
• Women of any reproductive status, using reliable contraception, with established ASCVD (prior MI, stroke, or peripheral artery disease) and LDL above 70 mg/dL on maximum statin plus ezetimibe
• Women with statin intolerance who cannot tolerate any statin dose and have significantly elevated baseline LDL
• Women with PCOS and very high cardiovascular risk, using reliable contraception

Women Who Should Not Use Praluent Now

• Women who are pregnant or planning pregnancy in the next 3-4 months
• Women who are breastfeeding
• Women with no documented ASCVD and LDL below 190 mg/dL who have not yet maximized statin and ezetimibe therapy (access and cost concerns aside, the evidence base for primary prevention with PCSK9 inhibitors remains thinner than for secondary prevention)

Women Who Need a Shared Decision Conversation First

• Perimenopausal women with FH who are approaching but have not reached menopause, where the LDL trajectory is rising but pregnancy is still possible
• Women with a history of recurrent pregnancy loss who are uncertain about future pregnancies and also have high cardiovascular risk

Storage, Self-Injection, and Practical Considerations

Praluent requires refrigeration at 36-46 degrees Fahrenheit (2-8 degrees Celsius). It can be stored at room temperature for up to 30 days before use, which simplifies travel. The pre-filled auto-injector pen is designed for self-injection into the abdomen, thigh, or upper arm. Injection-site reactions occur in roughly 7% of patients and are generally mild.

If your shipment from a specialty pharmacy is delayed, do not leave the pen at room temperature for more than 30 days. A pen that has been at room temperature for more than 30 days must be discarded.